Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORIN1001 in Advanced Solid Tumors
NCT05154201Phase 2Completed
- Sponsor
- Orinove Inc.
- Start
- Jul 2020
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ORIN1001 in solid tumor (advanced stage), Esophageal Squamous Cell Carcinoma (ESCC), triple-negative breast cancer (TNBC), breast cancer, hepatocellular carcinoma (HCC), sponsored by Orinove Inc.. Started Jul 2020; status: completed.
02
Drugs
ORIN1001
03
Conditions
solid tumor (advanced stage)Esophageal Squamous Cell Carcinoma (ESCC)triple-negative breast cancer (TNBC)breast cancerhepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05154201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05154201.